JP2017537611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537611A5 JP2017537611A5 JP2017522083A JP2017522083A JP2017537611A5 JP 2017537611 A5 JP2017537611 A5 JP 2017537611A5 JP 2017522083 A JP2017522083 A JP 2017522083A JP 2017522083 A JP2017522083 A JP 2017522083A JP 2017537611 A5 JP2017537611 A5 JP 2017537611A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- dna binding
- atr
- operably linked
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021213691A JP7623272B2 (ja) | 2014-10-24 | 2021-12-28 | 持続的エピジェネティック遺伝子サイレンシング |
| JP2025005873A JP2025063201A (ja) | 2014-10-24 | 2025-01-16 | 持続的エピジェネティック遺伝子サイレンシング |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1418965.8A GB201418965D0 (enExample) | 2014-10-24 | 2014-10-24 | |
| GB1418965.8 | 2014-10-24 | ||
| PCT/IB2015/058202 WO2016063264A1 (en) | 2014-10-24 | 2015-10-23 | Permanent epigenetic gene silencing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021213691A Division JP7623272B2 (ja) | 2014-10-24 | 2021-12-28 | 持続的エピジェネティック遺伝子サイレンシング |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537611A JP2017537611A (ja) | 2017-12-21 |
| JP2017537611A5 true JP2017537611A5 (enExample) | 2018-12-06 |
| JP7002936B2 JP7002936B2 (ja) | 2022-02-04 |
Family
ID=52103358
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522083A Active JP7002936B2 (ja) | 2014-10-24 | 2015-10-23 | 持続的エピジェネティック遺伝子サイレンシング |
| JP2021213691A Active JP7623272B2 (ja) | 2014-10-24 | 2021-12-28 | 持続的エピジェネティック遺伝子サイレンシング |
| JP2025005873A Pending JP2025063201A (ja) | 2014-10-24 | 2025-01-16 | 持続的エピジェネティック遺伝子サイレンシング |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021213691A Active JP7623272B2 (ja) | 2014-10-24 | 2021-12-28 | 持続的エピジェネティック遺伝子サイレンシング |
| JP2025005873A Pending JP2025063201A (ja) | 2014-10-24 | 2025-01-16 | 持続的エピジェネティック遺伝子サイレンシング |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12152240B2 (enExample) |
| EP (2) | EP3995584A1 (enExample) |
| JP (3) | JP7002936B2 (enExample) |
| CN (2) | CN107109433B (enExample) |
| AU (3) | AU2015334469B2 (enExample) |
| CA (1) | CA2965591A1 (enExample) |
| DK (1) | DK3209783T3 (enExample) |
| ES (1) | ES2906263T3 (enExample) |
| GB (1) | GB201418965D0 (enExample) |
| HU (1) | HUE057846T2 (enExample) |
| PL (1) | PL3209783T3 (enExample) |
| PT (1) | PT3209783T (enExample) |
| WO (1) | WO2016063264A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3597741A1 (en) | 2012-04-27 | 2020-01-22 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| GB201418965D0 (enExample) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| US12180263B2 (en) * | 2014-11-06 | 2024-12-31 | President And Fellows Of Harvard College | Cells lacking B2M surface expression and methods for allogeneic administration of such cells |
| JP6929791B2 (ja) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | エピゲノム編集のための組成物および方法 |
| CN115537396A (zh) * | 2015-03-27 | 2022-12-30 | 哈佛学院校长同事会 | 经过修饰的t细胞及其制备和使用方法 |
| US11674144B2 (en) * | 2015-04-16 | 2023-06-13 | California Institute Of Technology | Fractional regulation of transcription |
| CN107921148A (zh) | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| US11970710B2 (en) | 2015-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
| KR102787119B1 (ko) | 2015-11-30 | 2025-03-27 | 듀크 유니버시티 | 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법 |
| IL259576B (en) | 2015-12-04 | 2022-09-01 | Novartis Ag | grna molecule containing tracr and crrna, pharmaceutical composition containing it and method for preparing cells for immunotherapy |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| EP3463484B1 (en) * | 2016-05-27 | 2026-01-07 | The Regents of the University of California | Methods and compositions for targeting rna polymerases and non-coding rna biogenesis to specific loci |
| US20190100732A1 (en) * | 2016-06-02 | 2019-04-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Assay for the removal of methyl-cytosine residues from dna |
| EP4275747A3 (en) | 2016-07-19 | 2024-01-24 | Duke University | Therapeutic applications of cpf1-based genome editing |
| EP3500675A4 (en) | 2016-08-19 | 2020-01-29 | Whitehead Institute for Biomedical Research | Methods of editing dna methylation |
| WO2018049073A1 (en) | 2016-09-07 | 2018-03-15 | Flagship Pioneering, Inc. | Methods and compositions for modulating gene expression |
| US20200149039A1 (en) * | 2016-12-12 | 2020-05-14 | Whitehead Institute For Biomedical Research | Regulation of transcription through ctcf loop anchors |
| FI3565891T3 (fi) | 2017-01-09 | 2023-07-04 | Whitehead Inst Biomedical Res | Menetelmiä geeniekspression muuttamiseksi häiritsemällä säätelysilmukoita muodostavia transkriptiotekijämultimeerejä |
| US20210322577A1 (en) * | 2017-03-03 | 2021-10-21 | Flagship Pioneering Innovations V, Inc. | Methods and systems for modifying dna |
| CA3054621A1 (en) | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| IL270415B2 (en) | 2017-05-12 | 2024-08-01 | Crispr Therapeutics Ag | Materials and methods for cell engineering and their uses in immuno-oncology |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| US11072782B2 (en) | 2017-07-24 | 2021-07-27 | Albert-Ludwigs-Universitaet Freiburg | Construct for epigenetic modification and its use in the silencing of genes |
| CN107759673B (zh) * | 2017-09-27 | 2021-06-04 | 复旦大学 | 可对hbv的dna进行表观甲基化修饰的蛋白分子及其应用 |
| WO2019079462A1 (en) | 2017-10-17 | 2019-04-25 | President And Fellows Of Harvard College | TRANSCRIPTION MODULATION SYSTEMS BASED ON CAS9 |
| US12509492B2 (en) | 2018-01-19 | 2025-12-30 | Duke University | Genome engineering with CRISPR-Cas systems in eukaryotes |
| CN112334577B (zh) * | 2018-04-19 | 2023-10-17 | 加利福尼亚大学董事会 | 用于基因编辑的组合物和方法 |
| WO2019215500A1 (en) | 2018-05-11 | 2019-11-14 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| US20220016166A1 (en) * | 2018-09-21 | 2022-01-20 | Cafa Therapeutics Limited | T-cell expressing chimeric receptor |
| GB201817821D0 (en) * | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| EP3935170A4 (en) | 2019-03-05 | 2022-12-14 | Ramot at Tel-Aviv University Ltd. | PLANT DNA METHYLTRANSFERASES AND USES THEREOF |
| PE20212332A1 (es) | 2019-04-23 | 2021-12-14 | Sangamo Therapeutics Inc | Moduladores de la expresioon del gen de marco de lectura abierto 72 del cromosoma 9 y usos de los mismos |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| CA3147643A1 (en) | 2019-09-23 | 2021-04-01 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression |
| IL292329A (en) * | 2019-11-13 | 2022-06-01 | Crispr Therapeutics Ag | Manufacturing process for making t cells expressing chimeric antigen receptors |
| TW202132560A (zh) * | 2019-11-13 | 2021-09-01 | 瑞士商Ｃｒｉｓｐｒ治療公司 | 製備car-t細胞之方法 |
| US20230399640A1 (en) * | 2020-09-24 | 2023-12-14 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for inhibiting gene expression |
| KR20240011120A (ko) * | 2020-12-22 | 2024-01-25 | 크로마 메디슨, 인크. | 후성유전학적 편집을 위한 조성물 및 방법 |
| KR20230152689A (ko) * | 2021-02-01 | 2023-11-03 | 엡실렌 바이오 에스.알.엘. | 유전자 침묵 |
| CA3207426A1 (en) * | 2021-02-15 | 2022-08-18 | Vania Broccoli | Epigenetic silencing for treatment of cancer |
| JP2024534523A (ja) | 2021-09-21 | 2024-09-20 | スクライブ・セラピューティクス・インコーポレイテッド | 操作されたｃａｓｘリプレッサー系 |
| CN115247175B (zh) * | 2021-11-25 | 2025-10-17 | 南京启真基因工程有限公司 | 构建setdb1基因突变的表观遗传失调模型猪核移植供体细胞的基因编辑系统及其应用 |
| KR20240164823A (ko) * | 2022-03-04 | 2024-11-20 | 에피제닉 테라퓨틱스, 인코포레이티드 | 게놈 편집의 조성물및 방법 |
| EP4314267A1 (en) | 2022-06-07 | 2024-02-07 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| IL317913A (en) * | 2022-06-23 | 2025-02-01 | Chroma Medicine Inc | Compositions and methods for epigenetic regulation of B2M expression |
| US20250387514A1 (en) * | 2022-06-23 | 2025-12-25 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of trac expression |
| JP2025525389A (ja) * | 2022-06-23 | 2025-08-05 | エヌクロマ・バイオ，インコーポレーテッド | Ｃｉｉｔａ発現のエピジェネティック調節のための組成物及び方法 |
| JP2025521581A (ja) * | 2022-06-23 | 2025-07-10 | エヌクロマ・バイオ，インコーポレーテッド | エピジェネティック編集用の組成物および方法 |
| EP4544051A2 (en) | 2022-06-24 | 2025-04-30 | Tune Therapeutics, Inc. | Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression |
| EP4573200A2 (en) | 2022-08-19 | 2025-06-25 | Tune Therapeutics, Inc. | Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression |
| IL319704A (en) * | 2022-09-23 | 2025-05-01 | Nchroma Bio Inc | Compositions and methods for epigenetic regulation of HBV gene expression |
| WO2024081879A1 (en) * | 2022-10-14 | 2024-04-18 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of cd247 expression |
| AU2024220624A1 (en) | 2023-02-17 | 2025-09-11 | Whitehead Institute For Biomedical Research | Compositions and methods for making epigenetic modifications |
| WO2024220857A1 (en) * | 2023-04-20 | 2024-10-24 | Chroma Medicine, Inc. | Fusion proteins for epigenetic regulation |
| EP4713453A1 (en) | 2023-05-15 | 2026-03-25 | nChroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2024238700A1 (en) * | 2023-05-15 | 2024-11-21 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| IT202300011790A1 (it) | 2023-06-08 | 2024-12-08 | Fond Telethon Ets | Protocolli di manipolazione genica in cellule immunitarie |
| CN119464241A (zh) * | 2023-08-09 | 2025-02-18 | 厦门大学 | 瓜氨酸化setdb1多肽及其在诊断类风湿性关节炎中的应用 |
| WO2025160155A1 (en) | 2024-01-22 | 2025-07-31 | The Broad Institute, Inc. | Epigenetic targeting of prion diseases |
| CN121605133A (zh) * | 2024-06-21 | 2026-03-03 | 益杰立科(上海)生物科技有限公司 | 工程化基因转录阻抑工具及其用途 |
| EP4696705A1 (en) * | 2024-08-13 | 2026-02-18 | Fondazione Telethon ETS | Engineered transcription repressors and uses thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| WO1998005635A1 (en) | 1996-08-07 | 1998-02-12 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| US20020188103A1 (en) | 1998-10-09 | 2002-12-12 | Timothy H. Bestor | Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| DE60126483T2 (de) * | 2000-04-28 | 2007-12-06 | Sangamo BioSciences, Inc., Richmond | Gezielte Modifikation der Chromatinstruktur |
| US6919204B2 (en) | 2000-09-29 | 2005-07-19 | Sangamo Biosciences, Inc. | Modulation of gene expression using localization domains |
| WO2003072788A1 (en) * | 2002-02-21 | 2003-09-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for reversibly controlling expression of target genes in cells |
| CA2539439C (en) | 2003-09-19 | 2012-10-23 | Sangamo Biosciences, Inc. | Engineered zinc finger proteins for regulation of gene expression |
| US20070192880A1 (en) * | 2003-10-03 | 2007-08-16 | University Of Rochester | Horming response element binding transregulators |
| US7253273B2 (en) | 2004-04-08 | 2007-08-07 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
| GB0526449D0 (en) | 2005-12-23 | 2006-02-08 | Medical Res Council | Polypeptide targeting |
| KR100756055B1 (ko) | 2006-01-27 | 2007-09-07 | 연세대학교 산학협력단 | 신생혈관 생성을 조절하는 재조합 아데노바이러스 |
| GB0607063D0 (en) | 2006-04-07 | 2006-05-17 | Cellcentric Ltd | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo |
| GB0700374D0 (en) | 2007-01-09 | 2007-02-14 | Oncomethylome Sciences S A | NDRG family methylation markers |
| WO2010108126A2 (en) * | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Reprogramming compositions and methods of using the same |
| US9234016B2 (en) | 2009-07-28 | 2016-01-12 | Sangamo Biosciences, Inc. | Engineered zinc finger proteins for treating trinucleotide repeat disorders |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| GB201121924D0 (en) | 2011-12-20 | 2012-02-01 | Fahy Gurteen Labs Ltd | Detection of breast cancer |
| JP6309461B2 (ja) | 2012-02-28 | 2018-04-11 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ．， ＬＬＣ | ヒストンアセチル化の標的化 |
| NZ629427A (en) | 2012-02-29 | 2016-04-29 | Sangamo Biosciences Inc | Methods and compositions for treating huntington’s disease |
| IN2014DN06898A (enExample) | 2012-03-14 | 2015-05-15 | Salk Inst For Biological Studi | |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| PL4289948T3 (pl) | 2012-05-25 | 2025-06-02 | The Regents Of The University Of California | Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji |
| EP2912175B1 (en) | 2012-10-23 | 2018-08-22 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| CN105142669B (zh) | 2012-12-06 | 2018-07-03 | 西格马-奥尔德里奇有限责任公司 | 基于crispr的基因组修饰和调控 |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| CN105121648B (zh) | 2012-12-12 | 2021-05-07 | 布罗德研究所有限公司 | 用于序列操纵的系统、方法和优化的指导组合物的工程化 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| PT2898075E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências |
| CN105658796B (zh) | 2012-12-12 | 2021-10-26 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
| EP4282970A3 (en) | 2012-12-17 | 2024-01-17 | President and Fellows of Harvard College | Rna-guided human genome engineering |
| US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
| IL289396B2 (en) | 2013-03-15 | 2023-12-01 | The General Hospital Coporation | Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing |
| US20140356956A1 (en) | 2013-06-04 | 2014-12-04 | President And Fellows Of Harvard College | RNA-Guided Transcriptional Regulation |
| KR102307280B1 (ko) | 2013-06-05 | 2021-10-01 | 듀크 유니버시티 | Rna-가이드 유전자 편집 및 유전자 조절 |
| AU2014287397B2 (en) | 2013-07-10 | 2019-10-10 | President And Fellows Of Harvard College | Orthogonal Cas9 proteins for RNA-guided gene regulation and editing |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US20150191744A1 (en) | 2013-12-17 | 2015-07-09 | University Of Massachusetts | Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling |
| US10323073B2 (en) | 2014-03-20 | 2019-06-18 | UNIVERSITé LAVAL | CRISPR-based methods and products for increasing frataxin levels and uses thereof |
| CA2954791C (en) | 2014-07-14 | 2025-11-18 | The Regents Of The University Of California | CRISPR/CAS TRANSCRIPTIONAL MODULATION |
| WO2016011070A2 (en) | 2014-07-14 | 2016-01-21 | The Regents Of The University Of California | A protein tagging system for in vivo single molecule imaging and control of gene transcription |
| US20170233762A1 (en) | 2014-09-29 | 2017-08-17 | The Regents Of The University Of California | Scaffold rnas |
| US10583201B2 (en) | 2014-10-10 | 2020-03-10 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules in vitro and in vivo |
| GB201418965D0 (enExample) * | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| LT3250691T (lt) | 2015-01-28 | 2023-09-11 | Caribou Biosciences, Inc. | Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai |
| JP6929791B2 (ja) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | エピゲノム編集のための組成物および方法 |
| US10676735B2 (en) | 2015-07-22 | 2020-06-09 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
| US10525082B2 (en) | 2015-09-09 | 2020-01-07 | Seattle Children's Hospital | Genetic engineering of macrophages for immunotherapy |
| EP3147363B1 (en) | 2015-09-26 | 2019-10-16 | B.R.A.I.N. Ag | Activation of taste receptor genes in mammalian cells using crispr-cas-9 |
| JP6500293B2 (ja) | 2015-11-25 | 2019-04-17 | 国立大学法人群馬大学 | Ｄｎａメチル化編集用キットおよびｄｎａメチル化編集方法 |
-
2014
- 2014-10-24 GB GBGB1418965.8A patent/GB201418965D0/en not_active Ceased
-
2015
- 2015-10-23 US US15/521,294 patent/US12152240B2/en active Active
- 2015-10-23 AU AU2015334469A patent/AU2015334469B2/en active Active
- 2015-10-23 CN CN201580057762.8A patent/CN107109433B/zh active Active
- 2015-10-23 CN CN202211663401.6A patent/CN116789846A/zh active Pending
- 2015-10-23 ES ES15794644T patent/ES2906263T3/es active Active
- 2015-10-23 JP JP2017522083A patent/JP7002936B2/ja active Active
- 2015-10-23 PT PT157946443T patent/PT3209783T/pt unknown
- 2015-10-23 HU HUE15794644A patent/HUE057846T2/hu unknown
- 2015-10-23 DK DK15794644.3T patent/DK3209783T3/da active
- 2015-10-23 CA CA2965591A patent/CA2965591A1/en active Pending
- 2015-10-23 PL PL15794644T patent/PL3209783T3/pl unknown
- 2015-10-23 WO PCT/IB2015/058202 patent/WO2016063264A1/en not_active Ceased
- 2015-10-23 EP EP21197502.4A patent/EP3995584A1/en active Pending
- 2015-10-23 EP EP15794644.3A patent/EP3209783B1/en active Active
-
2021
- 2021-12-28 JP JP2021213691A patent/JP7623272B2/ja active Active
-
2022
- 2022-04-12 AU AU2022202407A patent/AU2022202407B2/en active Active
-
2025
- 2025-01-16 JP JP2025005873A patent/JP2025063201A/ja active Pending
- 2025-02-13 AU AU2025201007A patent/AU2025201007A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537611A5 (enExample) | ||
| JP7827321B2 (ja) | エピゲノム編集のための組成物および方法 | |
| CA3202977A1 (en) | Compositions and methods for epigenetic editing | |
| CN109640946A (zh) | 通过基因编辑策略进行hiv-1的负反馈调节 | |
| BR112019020001A2 (pt) | linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais | |
| JP2017525336A5 (enExample) | ||
| JP2020537545A (ja) | ｍＲＮＡの細胞内送達のためのペプチドおよびナノ粒子 | |
| JP2017524337A5 (enExample) | ||
| FI3988656T3 (fi) | Nukleosomien kanssa vuorovaikutteisten proteiinidomeenien käyttö tehostamaan kohdennettua genomimodifikaatiota | |
| BR112021009379A2 (pt) | anelossomos para entrega de modalidades terapêuticas secretadas | |
| EP3483275B1 (en) | Adipocyte-targeting non-viral gene delivery complex comprising dual plasmid vector | |
| JP2018528237A5 (enExample) | ||
| JP2015510393A5 (enExample) | ||
| WO2020127532A3 (en) | Rna encoding a protein | |
| US11857598B2 (en) | Self-replicating cell selective gene delivery compositions, methods, and uses thereof | |
| CN114592010A (zh) | NK-CAR-MbIL-15细胞及其制备方法和应用 | |
| JP2015529454A5 (enExample) | ||
| JP2020501574A5 (enExample) | ||
| CN116867901A (zh) | 功能性核酸分子和方法 | |
| Zaman et al. | Translational regulation of M13 gene II protein by its cognate single‐stranded DNA binding protein | |
| CN111574611B (zh) | 一种促进stat3活化的人源蛋白及其药物应用 | |
| JP2022502081A (ja) | 遺伝子操作された微生物ならびにそれを作製および使用する方法 | |
| RU2637371C2 (ru) | Гистоны и биодеградируемые липиды как средство для доставки нуклеиновых кислот в клетки эукариот | |
| Boroujeni et al. | Induction of Apoptosis and Autophagy Using Ectopic DSCR1 Expression in Breast Cancer Cells. | |
| JP2018512844A5 (enExample) |